Acquired Resistance ofEGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor-Reference-Cited by-同舟云学术

Acquired Resistance ofEGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor

Published:2015-10-01 Issue:7 Volume:1 Page:982
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Yu Helena A.¹,Tian Shaozhou K.²,Drilon Alexander E.¹,Borsu Laetitia²,Riely Gregory J.¹,Arcila Maria E.²,Ladanyi Marc³

Affiliation:

1. Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York2Department of Medicine, Weill Cornell Medical College, New York, New York

2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York

3. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York4Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 215 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a potent, selective, and orally available EGFR C797S mutant inhibitor (DS06652923) with in vivo antitumor activity;Bioorganic & Medicinal Chemistry;2024-09

2. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

3. Downregulation of Rad51 Expression and Activity Potentiates the Cytotoxic Effect of Osimertinib in Human Non-Small Cell Lung Cancer Cells;Chemotherapy;2024-08-10

4. Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study;Biomedicines;2024-06-25

5. Overcoming acquired resistance following osimertinib administration in EGFR-mutant lung adenocarcinoma;Translational Lung Cancer Research;2024-05